Patents by Inventor Zhongzhu Chen

Zhongzhu Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Spiro-?-Lactams, and preparation method and use thereof
    Patent number: 11827645
    Abstract: Disclosed is a compound of Formula I or a pharmaceutically acceptable salt thereof, preparation methods thereof, pharmaceutical composition comprising the same, and use thereof in the treatment of diseases such as pancreatic cancer.
    Type: Grant
    Filed: July 9, 2021
    Date of Patent: November 28, 2023
    Assignee: CHONGQING UNIVERSITY OF ARTS AND SCIENCES
    Inventors: Zhigang Xu, Zhongzhu Chen, Dianyong Tang
  • Benzimidazole derivatives, pharmaceutical composition comprising the same, and use thereof
    Patent number: 11512073
    Abstract: Disclosed is a compound of Formula I or a pharmaceutically acceptable salt thereof, and pharmaceutical composition comprising the same, and use thereof in the treatment of diseases benefiting from the inhibition of autophagic flux and/or chromatin ubiquitination, especially in the treatment of breast cancer.
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: November 29, 2022
    Assignee: CHONGQING UNIVERSITY OF ARTS AND SCIENCES
    Inventors: Zhongzhu Chen, Zhigang Xu, Dianyong Tang
  • SPIRO-gamma-LACTAMSAND, AND PREPARATION METHOD AND USE THEREOF
    Publication number: 20220009942
    Abstract: Disclosed is a compound of Formula I or a pharmaceutically acceptable salt thereof, preparation methods thereof, pharmaceutical composition comprising the same, and use thereof in the treatment of diseases such as pancreatic cancer.
    Type: Application
    Filed: July 9, 2021
    Publication date: January 13, 2022
    Applicant: Chongqing University of Arts and Sciences
    Inventors: Zhigang XU, Zhongzhu CHEN, Dianyong TANG
  • BENZIMIDAZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND USE THEREOF
    Publication number: 20210387970
    Abstract: Disclosed is a compound of Formula I or a pharmaceutically acceptable salt thereof, and pharmaceutical composition comprising the same, and use thereof in the treatment of diseases benefiting from the inhibition of autophagic flux and/or chromatin ubiquitination, especially in the treatment of breast cancer.
    Type: Application
    Filed: June 11, 2021
    Publication date: December 16, 2021
    Applicant: Chongqing University of Arts and Sciences
    Inventors: Zhongzhu CHEN, Zhigang XU, Dianyong TANG
  • Substituted pyrazino[1?,2?:1 ,6]pyrido[3,4-b]indoles as phosphodiesterase type 5 inhibitors
    Patent number: 9920057
    Abstract: Disclosed is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof as an inhibitor of phosphodiesterase type 5 and its therapeutic use in treating and/or preventing a disease or condition related with phosphodiesterase type 5 in a mammal wherein an inhibition of phosphodiesterase type 5 is considered beneficial
    Type: Grant
    Filed: November 30, 2015
    Date of Patent: March 20, 2018
    Assignee: Chongqing University of Arts and Sciences
    Inventors: Zhongzhu Chen, Zhigang Xu, Dianyong Tang
  • Novel Inhibitors of Phosphodiesterase Type 5 and their Therapeutic Uses
    Publication number: 20160376273
    Abstract: Disclosed is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof as an inhibitor of phosphodiesterase type 5 and its therapeutic use in treating and/or preventing a disease or condition related with phosphodiesterase type 5 in a mammal wherein an inhibition of phosphodiesterase type 5 is considered beneficial
    Type: Application
    Filed: November 30, 2015
    Publication date: December 29, 2016
    Inventors: Zhongzhu Chen, Zhigang Xu, Dianyong Tang